Business Standard

Sunday, December 22, 2024 | 08:34 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Don't slack off

Vaccination programme cannot lose govt attention

Covid vaccine
Premium

Business Standard Editorial Comment
The Indian vaccination programme against Covid-19 depended crucially on the Covishield vaccine produced by the Serum Institute of India and, to a lesser extent, on Bharat Biotech’s Covaxin. It has now been reported by this newspaper that both these companies have closed down some of their production lines and shifted resources to other vaccines, apparently because there are no more supply commitments. This cannot be viewed as unalloyed good news. While almost a billion first doses have been handed out in India, only 0.84 billion second doses have been administered as of Tuesday. In addition, only 12.3 million booster doses

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in